SI20360B - Sredstva in metode za zdravljenje motenj v zvezi z neuravnovešenostjo ter hiperaktivnih motenj v zvezi z neuravnovešenostjo s pomočjo metilfenidata - Google Patents
Sredstva in metode za zdravljenje motenj v zvezi z neuravnovešenostjo ter hiperaktivnih motenj v zvezi z neuravnovešenostjo s pomočjo metilfenidata Download PDFInfo
- Publication number
- SI20360B SI20360B SI9820083A SI9820083A SI20360B SI 20360 B SI20360 B SI 20360B SI 9820083 A SI9820083 A SI 9820083A SI 9820083 A SI9820083 A SI 9820083A SI 20360 B SI20360 B SI 20360B
- Authority
- SI
- Slovenia
- Prior art keywords
- methylphenidate
- agent
- polymer
- natural
- acrylic polymer
- Prior art date
Links
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 title claims abstract 25
- 229960001344 methylphenidate Drugs 0.000 title claims abstract 25
- 238000000034 method Methods 0.000 title claims abstract 3
- 239000000203 mixture Substances 0.000 title claims abstract 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 title abstract 6
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 title abstract 6
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 title abstract 3
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 title abstract 3
- 230000000699 topical effect Effects 0.000 claims abstract 12
- 239000003795 chemical substances by application Substances 0.000 claims 25
- 229920000058 polyacrylate Polymers 0.000 claims 15
- 229920000642 polymer Polymers 0.000 claims 10
- 229920005615 natural polymer Polymers 0.000 claims 9
- 229920001059 synthetic polymer Polymers 0.000 claims 9
- 239000000178 monomer Substances 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 210000004400 mucous membrane Anatomy 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 229920001296 polysiloxane Polymers 0.000 claims 3
- -1 polysiloxanes Polymers 0.000 claims 3
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims 2
- 239000000227 bioadhesive Substances 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 229920003052 natural elastomer Polymers 0.000 claims 2
- 229920001194 natural rubber Polymers 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 244000043261 Hevea brasiliensis Species 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 229920006397 acrylic thermoplastic Polymers 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229920001002 functional polymer Polymers 0.000 claims 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 229920003051 synthetic elastomer Polymers 0.000 claims 1
- 239000005061 synthetic rubber Substances 0.000 claims 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Izum se nanaša na metode za zdravljenje motenj vzvezi neuravnovešenostjo (ADD) ter hiperaktivnostnih motenj v zvezi neuravnovešenostjo (ADHD) kottudi na sredstva za topično uporabo metilfenidata v farmacevtsko spremljivem gibkem končnem sistemu, kjer je metilfenidat prisoten v količini, ki pri doziranju skozi pacientovo kožo ali sluznico zadostuje za doseganje kinetike v bistvu ničtega reda v časovnem obdobju vsaj 10 ur.
Description
* V tem dokumentu so objavljeni spremenjeni zahtevki patenta 20360 A. Zahtevki so bili spremenjeni na podlagi ugotovitvene odločbe, izdane po členu 93( 1 )(b)
Claims (23)
1. Sredstvo za topično uporabo metilfenidata, obsegajoče metilfenidat v fleksibilnem končnem sistemu, pri čemer sistem obsega naraven ali sintetičen polimer, ki ga je možno prilepiti na lokacijo topične aplikacije, in pri čemer je metilfenidat prisoten v količini od 20-180 mg metilfenidata na približno 2 do približno 60 cm2 z intenziteto doziranja od 0,5 do 100 mg/24 h, bolj prednostno od
2,5 do 20 mg/24 h, kar se odraža v vsebnostih metilfenidata v krvi, ki srednje vrednosti v ustaljenem stanju doziranja skozi pacientovo kožo ali sluznico v časovnem obdobju vsaj 10 ur ne presegajo za več kot 40%, in pri čemer, kadar polimer predstavlja akrilni polimer, sredstvo obsega največ 5 ut. % funkcionalnih kislinskih monomerov glede na maso akrilnega polimera.
2. Sredstvo po zahtevku 1, pri čemer se metilfenidat nahaja v obliki baze.
3. Sredstvo po zahtevku 1, pri čemer se metilfenidat nahaja v obliki kombinacije baze/bazične soli ali estra.
4. Sredstvo po zahtevku 1, pri čemer metilfenidat obsega pretežno enantiomer ά-threo- metilfenidata.
5. Sredstvo po zahtevku 1, pri čemer je naraven ali sintetičen polimer, ki ga je možno prilepiti na vsakokratno lokacijo topične uporabe, izbran iz skupine, ki sestoji iz akrilov, naravne in sintetične gume, bioadhezijskih sredstev, polisiloksanov, poliakrilatov, polivinilpirolidonov, kopolimerov vinilpirolidonov, blok polimerov stirena ter zmesi le-teh.
6. Sredstvo po zahtevku 5, pri čemer naraven ali sintetičen polimer, ki ga je možno prilepiti na vsakokratno lokacijo topične uporabe, vključuje bioadhezijsko sredstvo, izbrano iz skupine, ki sestoji iz naravnih ali umetnih polisaharidov in polimerov poliakrilnih kislin.
7. Sredstvo po zahtevku 6, pri čemer naravni polisaharid predstavlja naravna guma.
8. Sredstvo po zahtevku 5, pri čemer naraven ali sintetičen polimer, ki ga je možno prilepiti na vsakokratno lokacijo topične uporabe, vključuje polisiloksan, ki je nasičen ali amino-kompatibilen polimer polisiloksana.
9. Sredstvo po zahtevku 5, pri čemer naraven ali sintetičen polimer, ki ga je možno prilepiti na vsakokratno lokacijo topične uporabe, vključuje akril, ki je nefunkcionalen ali hidroksi-funkcionalen ali kar najmanj kislinsko funkcionalen polimer z največ 5 ut. % kislinsko funkcionalnih monomerov glede na maso akrilnega polimera.
10. Sredstvo po zahtevku 5, pri čemer naraven ali sintetičen polimer, ki gaje možno prilepiti na vsakokratno lokacijo topične uporabe, vključuje poliakrilat, ki je polimer brez vsebnosti vinil acetata.
11. Sredstvo po zahtevku 1, pri čemer se doziranje v kožo ali sluznico vrši v časovnem obdobju od približno 12 ur do približno 20 ur.
12. Sredstvo po zahtevku 1, pri čemer se doziranje v kožo ali sluznico vrši v časovnem obdobju od približno 14 ur do približno 16 ur.
2C
13. Sredstvo po zahtevku 2, pri čemer je baza metilfenidata v spojini prisotna v količini vsaj 26,4 mg na 10 cm .
14. Uporaba metilfenidata v fleksibilnem končnem sistemu za pripravo zdravila za zdravljenje motenj v zvezi neuravnovešenostjo ter hiperaktivnostnih motenj v zvezi neuravnovešenostjo, pri čemer sistem obsega naraven ali sintetičen polimer, ki gaje možno prilepiti na lokacijo topične aplikacije, in pri čemer je metilfenidat prisoten v količini od 20-180 mg metilfenidata na približno 2 do približno 60 cm z intenziteto doziranja od 0,5 do 100 mg/24 h, bolj prednostno od 2,5 do 20 mg/24 h, kar se odraža v vsebnostih metilfenidata v krvi, ki srednje vrednosti v ustaljenem stanju doziranja skozi pacientovo kožo ali sluznico v časovnem obdobju vsaj 10 ur ne presegajo za več kot 40%, in pri čemer, kadar polimer predstavlja akrilni polimer, sredstvo obsega največ 5 ut. % funkcionalnih kislinskih monomerov glede na maso akrilnega polimera.
15. Sredstvo za topično uporabo metilfenidata, obsegajoče metilfenidat v fleksibilnem končnem sistemu, pri čemer sistem obsega naraven ali sintetičen polimer, ki ga je možno prilepiti na lokacijo topične aplikacije, in pri čemer je metilfenidat prisoten v količini, ki zadostuje za zagotavljanje terapevtsko učinkovite doze pri pacientu v celotnem obdobju 24 ur, pri čemer celotna dozirana količina metilfenidata znaša od 0,5 mg do 100 mg, in pri čemer, kadar polimer predstavlja akrilni polimer, sredstvo obsega največ 5 ut. % funkcionalnih kislinskih monomerov glede na maso akrilnega polimera.
16. Sredstvo po zahtevku 15, pri čemer celotna količina doziranja metilfenidata znaša od 2,5 mg do 20 mg.
17. Sredstvo po zahtevku 15, pri čemer terapevtsko učinkovita doza znaša od 0,05 mg/kg/dan do 1,0 mg/kg/dan.
18. Sredstvo po zahtevku 15, pri čemer terapevtsko učinkovita doza znaša od 0,075 mg/kg/dan do 0,3 mg/kg/dan.
19. Uporaba metilfenidata v fleksibilnem končnem sistemu za pripravo zdravila za zdravljenje motenj v zvezi neuravnovešenostjo ter hiperaktivnostnih motenj v zvezi neuravnovešenostjo, pri čemer sistem obsega naraven ali sintetičen polimer, ki gaje možno prilepiti na lokacijo topične aplikacije, in pri čemer je metilfenidat prisoten v količini, ki zadostuje za dovajanje terapevtsko učinkovite doze pacientu preko celotnega obdobja 24 ur, pri čemer celotna količina doziranja metilfenidata znaša od 0,5 mg do 100 mg, in pri čemer, kadar polimer predstavlja akrilni polimer, sredstvo obsega največ 5 ut. % funkcionalnih kislinskih monomerov glede na maso akrilnega polimera.
20. Sredstvo po zahtevku 16, pri čemer terapevtsko učinkovita doza znaša od 0,05 mg/kg/dan do 1,0 mg/kg/dan.
21. Sredstvo po zahtevku 16, pri čemer terapevtsko učinkovita doza znaša od 0,075 mg/kg/dan do 0,3 mg/kg/dan.
22. Sredstvo po zahtevku 1 ali po zahtevku 15, pri čemer, kadar polimer predstavlja akrilni polimer, spojina obsega največ 1 ut. % funkcionalnih kislinskih monomerov glede na maso akrilnega polimera.
£
23. Sredstvo po zahtevku 14 ali po zahtevku 19, pri čemer, kadar polimer predstavlja akrilni polimer, spojina obsega največ 1 ut. % funkcionalnih kislinskih monomerov glede na maso akrilnega polimera.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6951097P | 1997-12-15 | 1997-12-15 | |
| US09/163,351 US6210705B1 (en) | 1997-12-15 | 1998-09-30 | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
| PCT/US1998/026560 WO1999030694A2 (en) | 1997-12-15 | 1998-12-14 | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SI20360A SI20360A (sl) | 2001-04-30 |
| SI20360B true SI20360B (sl) | 2008-06-30 |
Family
ID=26750154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI9820083A SI20360B (sl) | 1997-12-15 | 1998-12-14 | Sredstva in metode za zdravljenje motenj v zvezi z neuravnovešenostjo ter hiperaktivnih motenj v zvezi z neuravnovešenostjo s pomočjo metilfenidata |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US6210705B1 (sl) |
| EP (2) | EP2314288B1 (sl) |
| JP (3) | JP4316800B2 (sl) |
| KR (1) | KR100633348B1 (sl) |
| CN (1) | CN1368876A (sl) |
| AR (1) | AR014062A1 (sl) |
| AT (1) | ATE260652T1 (sl) |
| AU (1) | AU752027B2 (sl) |
| BR (1) | BR9814282A (sl) |
| CA (1) | CA2315237C (sl) |
| CZ (2) | CZ300535B6 (sl) |
| DE (1) | DE69822199T2 (sl) |
| DK (1) | DK1037615T3 (sl) |
| ES (2) | ES2219926T3 (sl) |
| HK (1) | HK1049447A1 (sl) |
| HU (1) | HU226615B1 (sl) |
| IL (1) | IL136760A0 (sl) |
| LV (1) | LV12558B (sl) |
| NO (1) | NO329974B1 (sl) |
| NZ (1) | NZ505689A (sl) |
| PE (1) | PE20000120A1 (sl) |
| PL (1) | PL195315B1 (sl) |
| PT (1) | PT1037615E (sl) |
| RU (1) | RU2233156C2 (sl) |
| SI (1) | SI20360B (sl) |
| TR (1) | TR200001736T2 (sl) |
| TW (2) | TWI244396B (sl) |
| WO (1) | WO1999030694A2 (sl) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| US20020102291A1 (en) * | 1997-12-15 | 2002-08-01 | Noven Pharmaceuticals, Inc. | Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
| GB9913458D0 (en) * | 1999-06-09 | 1999-08-11 | Medeva Europ Ltd | The therapeutic use of d-threo-methylphenidate |
| GB9918735D0 (en) * | 1999-08-09 | 1999-10-13 | Straken Limited | Transdermal patches |
| CO5261532A1 (es) * | 1999-11-15 | 2003-03-31 | Novartis Ag | Compuestos heterociclicos sililados, procedimiento para la preparacion de estos y composicion farmaceutica que los contiene |
| WO2001043730A2 (en) * | 1999-12-17 | 2001-06-21 | Medeva Europe Limited | The treatment of convulsive states |
| US6455066B1 (en) | 2000-03-10 | 2002-09-24 | Epicept Corporation | Intradermal-penetration agents for topical local anesthetic administration |
| US6905016B2 (en) * | 2000-03-14 | 2005-06-14 | Noven Pharmaceuticals, Inc. | Packaging system for transdermal drug delivery systems |
| US7674480B2 (en) * | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| US20020119187A1 (en) * | 2000-09-29 | 2002-08-29 | Cantor Adam S. | Composition for the transdermal delivery of fentanyl |
| DE10060550C1 (de) * | 2000-12-06 | 2002-04-18 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten |
| KR100846642B1 (ko) * | 2001-03-07 | 2008-07-16 | 히사미쓰 세이야꾸 가부시키가이샤 | 첩부제 |
| FR2822049B1 (fr) * | 2001-03-13 | 2003-08-01 | Dbv Medica 1 | Patch destine notamment a depister l'etat de sensibilisation d'un sujet a un allergene, procede de fabrication et utilisation |
| MXPA03008349A (es) * | 2001-03-16 | 2004-10-15 | Johnson & Johnson | Parche transdermico para administrar fentanilo. |
| US20050208117A1 (en) * | 2001-03-16 | 2005-09-22 | Venkatraman Subramanian S | Transdermal administration of fentanyl and analogs thereof |
| DE10141652B4 (de) * | 2001-08-24 | 2011-04-07 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung |
| DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
| US20030049272A1 (en) * | 2001-08-30 | 2003-03-13 | Yatindra Joshi | Pharmaceutical composition which produces irritation |
| JP4354678B2 (ja) * | 2002-08-28 | 2009-10-28 | 久光製薬株式会社 | 貼付剤 |
| US6913768B2 (en) | 2002-09-24 | 2005-07-05 | Shire Laboratories, Inc. | Sustained release delivery of amphetamine salts |
| EP1575569B1 (en) | 2002-12-13 | 2010-09-29 | Durect Corporation | Oral drug delivery system comprising high viscosity liquid carrier materials |
| CN100457064C (zh) * | 2003-10-28 | 2009-02-04 | 诺芬药品公司 | 透皮递药装置 |
| CA2595400C (en) | 2005-01-20 | 2017-01-17 | Institute For Molecular Medicine, Inc. | Methylphenidate derivatives and their use in the treatment of angiogenic diseases and conditions |
| EP1845780B1 (en) * | 2005-01-20 | 2011-07-27 | Institute for Molecular Medicine, Inc. | Uses of methylphenidate derivatives |
| WO2007077029A1 (de) * | 2005-12-23 | 2007-07-12 | Epinamics Gmbh | Verwendung filmbildender haarpflegepolymere aus der gruppe der polyurethane und diese polymere enthaltende pharmazeutische zubereitungen und pflaster |
| US9393218B2 (en) * | 2005-12-23 | 2016-07-19 | Epinamics Gmbh | Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers |
| MX2008010934A (es) * | 2006-02-27 | 2008-10-30 | Noven Pharma | Sistema terapeutico transdermico que contiene escopolamina. |
| AU2007248284B2 (en) * | 2006-05-01 | 2011-03-17 | Colgate-Palmolive Company | Oral care composition with silicone composite |
| WO2008103538A1 (en) * | 2007-02-21 | 2008-08-28 | Connected Health Systems, Llc | Treating adhd and other diseases involving inflammation |
| CN104398496B (zh) * | 2007-10-15 | 2018-03-20 | 阿尔扎公司 | 芬太尼的一天更换一次透皮施用 |
| FR2924350B1 (fr) * | 2007-12-03 | 2010-08-13 | Dbv Tech | Procede et compositions pour la vaccination par voie cutanee |
| FR2924349B1 (fr) | 2007-12-03 | 2010-01-01 | Dbv Tech | Methode de desensibilitation aux allergenes |
| EP2219622A1 (en) | 2007-12-06 | 2010-08-25 | Durect Corporation | Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition |
| EP2234652B1 (en) * | 2007-12-31 | 2014-09-24 | Acclarent, Inc. | Mucosal tissue dressing and method of use |
| FR2926466B1 (fr) * | 2008-01-23 | 2010-11-12 | Dbv Tech | Procede de fabrication de patchs par electrospray |
| US8217047B2 (en) * | 2008-05-27 | 2012-07-10 | Dmi Acquisition Corp. | Therapeutic methods and compounds |
| US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
| JP5155128B2 (ja) * | 2008-12-11 | 2013-02-27 | 日東電工株式会社 | メチルフェニデート貼付製剤 |
| WO2010141587A1 (en) * | 2009-06-05 | 2010-12-09 | Megtec Systems, Inc. | Improved infrared float bar |
| EP2364695A1 (en) | 2010-02-10 | 2011-09-14 | Nitto Denko Corporation | Methylphenidate patch preparation |
| US20110200663A1 (en) * | 2010-02-12 | 2011-08-18 | Nitto Denko Corporation | Methylphenidate patch preparation |
| US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9119809B2 (en) | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
| US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US10292937B2 (en) | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
| US8916588B2 (en) | 2011-03-23 | 2014-12-23 | Ironshore Pharmaceuticals & Development, Inc. | Methods for treatment of attention deficit hyperactivity disorder |
| US9283214B2 (en) | 2011-03-23 | 2016-03-15 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| ES2973539T3 (es) | 2011-03-23 | 2024-06-20 | Ironshore Pharmaceuticals & Dev Inc | Métodos y composiciones para el tratamiento del trastorno por déficit de atención |
| US8927010B2 (en) | 2011-03-23 | 2015-01-06 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| HRP20170555T1 (hr) | 2011-07-28 | 2017-06-16 | Kempharm, Inc. | Metilfenidatni prolijekovi, postupci za njihovo dobivanje i njihova primjena |
| US9717697B2 (en) | 2012-10-15 | 2017-08-01 | Noven Pharmaceuticals, Inc. | Compositions and methods for the transdermal delivery of methylphenidate |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| ES2864327T3 (es) | 2012-12-28 | 2021-10-13 | Noven Pharma | Composiciones de múltiples polímeros para la administración transdérmica de fármacos |
| TW201431554A (zh) | 2012-12-28 | 2014-08-16 | Noven Pharma | 左炔諾孕酮（ｌｅｖｏｎｏｒｇｅｓｔｒｅｌ）及乙烯雌二醇之經皮藥物遞送系統 |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
| US11337936B2 (en) | 2013-03-14 | 2022-05-24 | Noven Pharmaceuticals, Inc. | Amphetamine transdermal compositions with acrylic block copolymer |
| JP2016515523A (ja) | 2013-03-15 | 2016-05-30 | デュレクト コーポレーション | 溶解変動性を低減させるためのレオロジー改質剤を有する組成物 |
| AR095260A1 (es) | 2013-03-15 | 2015-09-30 | Noven Pharma | Composiciones de anfetaminas transdérmicas estables y métodos de fabricación |
| AR095259A1 (es) | 2013-03-15 | 2015-09-30 | Noven Pharma | Composiciones y métodos para la administración transdérmica de fármacos de amina terciaria |
| US9782383B2 (en) | 2013-12-25 | 2017-10-10 | Fujimoto Co., Ltd. | Prophylactic and therapeutic agent for attention-deficit/hyperactivity disorder |
| US9980921B2 (en) * | 2016-06-30 | 2018-05-29 | Taho Pharmaceuticals Ltd. | Transdermal delivery system containing methylphenidate or its salts and methods thereof |
| MY205229A (en) | 2016-07-06 | 2024-10-08 | Durect Corp | Oral dosage form with drug composition, barrier layer and drug layer |
| CN106511264A (zh) * | 2016-11-15 | 2017-03-22 | 北京万全德众医药生物技术有限公司 | 一种盐酸哌甲酯口服溶液剂及其制备方法 |
| ES2979262T3 (es) | 2016-12-11 | 2024-09-25 | Zevra Therapeutics Inc | Composiciones que comprenden metilfenidato-profármacos, procesos de elaboración y uso de las mismas |
| EP3598982A1 (en) | 2018-07-23 | 2020-01-29 | Centre National De La Recherche Scientifique | Bioconjugates of neuropeptides derivatives |
| JP7600661B2 (ja) * | 2020-12-11 | 2024-12-17 | ａｒｔｉｅｎｃｅ株式会社 | 貼付剤 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2957880A (en) | 1953-12-23 | 1960-10-25 | Ciba Pharm Prod Inc | Process for the conversion of stereoisomers |
| US4310509A (en) | 1979-07-31 | 1982-01-12 | Minnesota Mining And Manufacturing Company | Pressure-sensitive adhesive having a broad spectrum antimicrobial therein |
| US4655767A (en) | 1984-10-29 | 1987-04-07 | Dow Corning Corporation | Transdermal drug delivery devices with amine-resistant silicone adhesives |
| US5474783A (en) | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5656286A (en) | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| DE3910578A1 (de) * | 1989-03-29 | 1990-10-04 | Schering Ag | Mittel zur transdermalen applikation enthaltend gestoden |
| JP2693212B2 (ja) * | 1989-03-28 | 1997-12-24 | 日東電工株式会社 | 疾患治療用テープ製剤 |
| WO1992021333A2 (en) * | 1991-05-24 | 1992-12-10 | Pharmavene, Inc. | Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors |
| US5629019A (en) | 1992-02-27 | 1997-05-13 | Alza Corporation | Formulations with hydrophobic permeation enhancers |
| ATE152630T1 (de) | 1992-07-28 | 1997-05-15 | Procter & Gamble | Pharmazeutische zusammensetzung zur topischen anwendung die ein vernetztes kationisches polymer und einen alkoxylierte äther enthält |
| CH691209A5 (de) | 1993-09-06 | 2001-05-15 | Scherrer Inst Paul | Herstellungsverfahren für einen Polmerelektrolyten und elektrochemische Zelle mit diesem Polymerelektrolyten. |
| ES2139778T3 (es) | 1994-06-29 | 2000-02-16 | Hennecke Gmbh | Procedimiento y dispositivo para la fabricacion continua de bloques o bandas de material de espuma. |
| US5601839A (en) | 1995-04-26 | 1997-02-11 | Theratech, Inc. | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
| US5780050A (en) | 1995-07-20 | 1998-07-14 | Theratech, Inc. | Drug delivery compositions for improved stability of steroids |
| AU2590697A (en) | 1997-03-07 | 1998-09-22 | Richard R. Jackson | Anesthetizing plastics, drug delivery plastics, and related medical products, s ystems and methods |
| GB9711032D0 (en) | 1997-05-30 | 1997-07-23 | Johnson Matthey Plc | Compound as a stimulant for the central nervous system |
| EP1710506A2 (en) | 1999-12-15 | 2006-10-11 | Osaka Gas Co., Ltd. | Burner Apparatus, Gas Turbine Engine and Cogeneration System |
-
1998
- 1998-09-30 US US09/163,351 patent/US6210705B1/en not_active Expired - Lifetime
- 1998-12-14 CZ CZ20002209A patent/CZ300535B6/cs not_active IP Right Cessation
- 1998-12-14 RU RU2000119097/15A patent/RU2233156C2/ru not_active IP Right Cessation
- 1998-12-14 CZ CZ2009-132A patent/CZ305817B6/cs not_active IP Right Cessation
- 1998-12-14 HK HK03101632.9A patent/HK1049447A1/zh unknown
- 1998-12-14 NZ NZ505689A patent/NZ505689A/xx not_active IP Right Cessation
- 1998-12-14 TW TW092128573A patent/TWI244396B/zh not_active IP Right Cessation
- 1998-12-14 BR BR9814282-8A patent/BR9814282A/pt not_active Application Discontinuation
- 1998-12-14 SI SI9820083A patent/SI20360B/sl not_active IP Right Cessation
- 1998-12-14 HU HU0004539A patent/HU226615B1/hu not_active IP Right Cessation
- 1998-12-14 ES ES98963170T patent/ES2219926T3/es not_active Expired - Lifetime
- 1998-12-14 IL IL13676098A patent/IL136760A0/xx not_active IP Right Cessation
- 1998-12-14 DE DE69822199T patent/DE69822199T2/de not_active Expired - Lifetime
- 1998-12-14 CA CA002315237A patent/CA2315237C/en not_active Expired - Lifetime
- 1998-12-14 TR TR2000/01736T patent/TR200001736T2/xx unknown
- 1998-12-14 PT PT98963170T patent/PT1037615E/pt unknown
- 1998-12-14 JP JP2000538677A patent/JP4316800B2/ja not_active Expired - Lifetime
- 1998-12-14 KR KR1020007006477A patent/KR100633348B1/ko not_active Expired - Fee Related
- 1998-12-14 EP EP10011358.8A patent/EP2314288B1/en not_active Expired - Lifetime
- 1998-12-14 AU AU18249/99A patent/AU752027B2/en not_active Ceased
- 1998-12-14 ES ES10011358.8T patent/ES2452517T3/es not_active Expired - Lifetime
- 1998-12-14 DK DK98963170T patent/DK1037615T3/da active
- 1998-12-14 WO PCT/US1998/026560 patent/WO1999030694A2/en not_active Ceased
- 1998-12-14 EP EP98963170A patent/EP1037615B1/en not_active Expired - Lifetime
- 1998-12-14 AT AT98963170T patent/ATE260652T1/de active
- 1998-12-14 PL PL98341596A patent/PL195315B1/pl unknown
- 1998-12-14 CN CN98813634A patent/CN1368876A/zh active Pending
- 1998-12-14 TW TW087120741A patent/TWI242452B/zh not_active IP Right Cessation
- 1998-12-15 AR ARP980106392A patent/AR014062A1/es not_active Application Discontinuation
- 1998-12-15 PE PE1998001219A patent/PE20000120A1/es not_active Application Discontinuation
-
2000
- 2000-06-15 NO NO20003096A patent/NO329974B1/no not_active IP Right Cessation
- 2000-07-17 LV LVP-00-92A patent/LV12558B/en unknown
- 2000-07-18 US US09/618,626 patent/US6348211B1/en not_active Expired - Lifetime
-
2008
- 2008-11-13 JP JP2008291364A patent/JP2009073856A/ja active Pending
-
2012
- 2012-12-26 JP JP2012282405A patent/JP2013056944A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI20360B (sl) | Sredstva in metode za zdravljenje motenj v zvezi z neuravnovešenostjo ter hiperaktivnih motenj v zvezi z neuravnovešenostjo s pomočjo metilfenidata | |
| RU2000119097A (ru) | Композиция для местного применения метилфенидата (варианты) и способ лечения расстройства дефицита внимания и расстройства типа дефицита внимания/гиперактивности (варианты) | |
| US5750134A (en) | Bioadhesive composition and patch | |
| US5750136A (en) | Bioadhesive composition and patch | |
| AU784779B2 (en) | Ultraviolet-shielding adhesive preparation | |
| RU2001111025A (ru) | Фармацевтическая композиция для лечения острых нарушений | |
| MY106628A (en) | Estrogen-containing active substance plaster | |
| DE59907676D1 (de) | Wässrige Dispersion geeignet zur Herstellung von Überzugs- und Bindemitteln für feste orale Arzneiformen | |
| ATE261278T1 (de) | Mikrokapseln zum verabreichen von neuroaktiven wirkstoffen | |
| DE69526934D1 (de) | Medikamente zur behandlung von restenosis, enthaltend stickstoff freisetzende polymere | |
| IL112674A (en) | Sustained release liquid aqueous ophthalmic delivery system and liquid aqueous ophthalmic pharmaceutical composition both containing the polymer chitosan | |
| JP2001508442A (ja) | ポリマーを使用して粘度付与したヒドロアルコール組成物 | |
| DE69325402D1 (de) | Verbessertes System des Typs einmal täglich zur gepulsten Minocyclinabgabe | |
| ATE230426T1 (de) | Überzugs- und bindemittel für orale oder dermale arzneiformen | |
| BR9916361A (pt) | Forma de dosagem de tabletes de liberação controlada, formulação de tablete de liberação controlada, composição granular para prensagem em uma forma de dosagem de tablete de liberação controlada, e, métodos para preparar uma composição granular, para preparar uma forma de dosagem de tabletes de liberação controlada de divalproex sódio e para tratar epilepsia | |
| JP2000501790A (ja) | 組成物と使用 | |
| WO2002098464A3 (en) | Liquid polymer composition for prevention and treatment of the oral cavity diseases | |
| US20060257504A1 (en) | Compositions for the preparation of carbon dioxide gel for external use and carbon dioxide gels for external use | |
| EP1125578A1 (en) | Tape material for transcutaneous absorption | |
| AU8444291A (en) | Controlled release formulations and method | |
| IL115189A0 (en) | A transdermal therapeutic system containing scopolamine | |
| AU595198B2 (en) | The use of an aqueous swollen macromolecule-containing system as water for fire fighting | |
| CA2374039A1 (en) | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations | |
| ATE183384T1 (de) | Lactulose-pastillen | |
| DE19829713C1 (de) | Therapeutisches System mit Zusatz von Perglanzpigmenten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF | Valid on the event date | ||
| OU02 | Decision according to article 73(2) ipa 1992, publication of decision on partial fulfilment of the invention and change of patent claims |
Effective date: 20080321 |
|
| KO00 | Lapse of patent |
Effective date: 20180807 |